Actavis plc, of Dublin, said its subsidiary, Watson Laboratories Inc., filed suit against the FDA regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.